| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1028267128 |
| P356 | DOI | 10.1186/1472-6939-15-54 |
| P932 | PMC publication ID | 4086269 |
| P698 | PubMed publication ID | 24994501 |
| P5875 | ResearchGate publication ID | 263743915 |
| P50 | author | Kimberly Thomson | Q93265256 |
| P2093 | author name string | Will Small | |
| Jean Shoveller | |||
| Rod Knight | |||
| Basia Pakula | |||
| P2860 | cites work | Scoping studies: advancing the methodology | Q24570529 |
| Combination implementation for HIV prevention: moving from clinical trial evidence to population-level effects | Q24610019 | ||
| Prevention of HIV-1 infection with early antiretroviral therapy | Q24634688 | ||
| Treatment-related optimistic beliefs and risk of HIV transmission: a review of recent findings (2009-2012) in an era of treatment as prevention | Q27023036 | ||
| Clinical uncertainties, health service challenges, and ethical complexities of HIV "test-and-treat": a systematic review | Q27026742 | ||
| Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model | Q29305377 | ||
| Transcending the Known in Public Health Practice | Q29541256 | ||
| Articulating a rights-based approach to HIV treatment and prevention interventions | Q30224939 | ||
| Treating our way out of the HIV pandemic: could we, would we, should we? | Q30373536 | ||
| Biomedical strategies for human immunodeficiency virus (HIV) prevention? A new paradigm. | Q30425703 | ||
| Associations between the legal context of HIV, perceived social capital, and HIV antiretroviral adherence in North America. | Q31125998 | ||
| Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco | Q33604727 | ||
| Study designs for identifying risk compensation behavior among users of biomedical HIV prevention technologies: balancing methodological rigor and research ethics | Q33718608 | ||
| Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial | Q34086963 | ||
| Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study | Q34126545 | ||
| Treatment as prevention--a double hat-trick | Q34201017 | ||
| Can we stop AIDS with antiretroviral-based treatment as prevention? | Q34210416 | ||
| HIV treatment as prevention: issues in economic evaluation | Q34339555 | ||
| A commentary on studies presenting projections of the future prevalence of dementia | Q34528846 | ||
| The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic | Q34554572 | ||
| High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa | Q34629087 | ||
| When to start antiretroviral therapy: the need for an evidence base during early HIV infection | Q34773308 | ||
| Interventions to improve the performance of HIV health systems for treatment-as-prevention in sub-Saharan Africa: the experimental evidence | Q34990011 | ||
| Treatment as prevention: preparing the way | Q35357663 | ||
| Given financial constraints, it would be unethical to divert antiretroviral drugs from treatment to prevention | Q36611163 | ||
| Oral antiretroviral drugs as public health tools for HIV prevention: global implications for adherence, drug resistance, and the success of HIV treatment programs | Q37003938 | ||
| Reaping the prevention benefits of highly active antiretroviral treatment: policy implications of HIV Prevention Trials Network 052. | Q37974037 | ||
| Fifteen million people on antiretroviral treatment by 2015: treatment as prevention | Q38063142 | ||
| Antiretroviral therapy for prevention is a combination strategy | Q38078278 | ||
| Antiretroviral therapy for prevention of HIV and tuberculosis: a promising intervention but not a panacea | Q39400108 | ||
| Separate goals, converging priorities: on the ethics of treatment as prevention | Q42257530 | ||
| A review of barriers and facilitators of HIV treatment among injection drug users. | Q43066134 | ||
| Antiretroviral resource allocation for HIV prevention | Q43749276 | ||
| Ethics of ARV based prevention: treatment-as-prevention and PrEP. | Q46372939 | ||
| Test and treat in HIV: success could depend on rapid detection | Q46434133 | ||
| Don't solve the issues! A plea for ambiguity within empirical ethics | Q48411958 | ||
| The devil in the details: thorough assessment of evidence and ethics is needed in evaluating new HIV prevention methods | Q48435069 | ||
| Social science and bioethics: the way forward | Q50183845 | ||
| Antiretrovirals for HIV prevention: translating promise into praxis. | Q51547767 | ||
| Does the inclusion of grey literature influence estimates of intervention effectiveness reported in meta-analyses? | Q52926541 | ||
| Risk, Risk Groups and Population Health | Q57612348 | ||
| Could do Better: Research Data Sharing and Public Health | Q57612362 | ||
| Treatment-as-Prevention Needs to Be Considered in the Just Allocation of HIV Drugs | Q57989206 | ||
| Stigma and the ethics of public health: not can we but should we | Q58671130 | ||
| Rose's population strategy of prevention need not increase social inequalities in health | Q59365712 | ||
| HPTN 052 and the future of HIV treatment and prevention | Q84565642 | ||
| Treatment as prevention for HIV | Q84829483 | ||
| Remedicalizing an epidemic: from HIV treatment as prevention to HIV treatment is prevention | Q85230999 | ||
| P921 | main subject | research ethics | Q1132684 |
| prevention of HIV/AIDS | Q7242372 | ||
| P304 | page(s) | 54 | |
| P577 | publication date | 2014-07-03 | |
| P1433 | published in | BMC Medical Ethics | Q15762173 |
| P1476 | title | A scoping study to identify opportunities to advance the ethical implementation and scale-up of HIV treatment as prevention: priorities for empirical research | |
| P478 | volume | 15 |
| Q36272141 | Clinical ethics issues in HIV care in Canada: an institutional ethnographic study |
| Q35891499 | Complex and Conflicting Social Norms: Implications for Implementation of Future HIV Pre-Exposure Prophylaxis (PrEP) Interventions in Vancouver, Canada |
| Q36463726 | HIV stigma and the experiences of young men with voluntary and routine HIV testing |
| Q35956696 | Implementation challenges and opportunities for HIV Treatment as Prevention (TasP) among young men in Vancouver, Canada: a qualitative study |
| Q37125639 | Plasma HIV-1 RNA viral load rebound among people who inject drugs receiving antiretroviral therapy (ART) in a Canadian setting: an ethno-epidemiological study |
Search more.